What is Wedbush’s Forecast for ELEV FY2029 Earnings?

Elevation Oncology, Inc. (NASDAQ:ELEV) – Equities research analysts at Wedbush issued their FY2029 earnings per share estimates for Elevation Oncology in a research note issued to investors on Friday, March 7th. Wedbush analyst R. Driscoll anticipates that the company will earn $0.07 per share for the year. The consensus estimate for Elevation Oncology’s current full-year earnings is ($0.84) per share.

ELEV has been the subject of several other research reports. William Blair restated an “outperform” rating and issued a $5.00 price objective on shares of Elevation Oncology in a research report on Friday. HC Wainwright restated a “buy” rating and issued a $6.00 price objective on shares of Elevation Oncology in a research report on Tuesday, January 14th. Stephens restated an “overweight” rating and issued a $5.00 price objective on shares of Elevation Oncology in a research report on Friday. Finally, JMP Securities reiterated a “market outperform” rating and set a $7.00 target price on shares of Elevation Oncology in a research report on Thursday, December 19th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of “Buy” and an average price target of $6.83.

Elevation Oncology Stock Down 0.0 %

NASDAQ ELEV opened at $0.51 on Monday. The company has a current ratio of 17.77, a quick ratio of 17.77 and a debt-to-equity ratio of 0.45. The stock’s 50 day moving average is $0.64 and its two-hundred day moving average is $0.62. The company has a market capitalization of $30.20 million, a price-to-earnings ratio of -0.62 and a beta of 1.37. Elevation Oncology has a 1-year low of $0.41 and a 1-year high of $5.83.

Elevation Oncology (NASDAQ:ELEV) last posted its quarterly earnings data on Thursday, March 6th. The company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.04.

Hedge Funds Weigh In On Elevation Oncology

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ELEV. Velan Capital Investment Management LP acquired a new position in shares of Elevation Oncology during the 4th quarter worth about $25,000. Bank of America Corp DE raised its holdings in Elevation Oncology by 42.5% in the 4th quarter. Bank of America Corp DE now owns 56,839 shares of the company’s stock valued at $32,000 after acquiring an additional 16,962 shares during the period. JPMorgan Chase & Co. raised its holdings in Elevation Oncology by 175.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 61,334 shares of the company’s stock valued at $37,000 after acquiring an additional 39,101 shares during the period. SG Americas Securities LLC raised its holdings in Elevation Oncology by 33.9% in the 4th quarter. SG Americas Securities LLC now owns 61,467 shares of the company’s stock valued at $35,000 after acquiring an additional 15,560 shares during the period. Finally, Two Sigma Securities LLC bought a new position in Elevation Oncology in the 4th quarter valued at about $35,000. 83.70% of the stock is owned by institutional investors and hedge funds.

Elevation Oncology Company Profile

Elevation Oncology, Inc, an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target.